Investors Are Waking Up To Psyence Biomedical Ltd (NASDAQ: PBM) After Losing -99.71% Over The Past 12 Months

Psyence Biomedical Ltd (NASDAQ:PBM) currently has a daily average trading volume of 762.26K but it saw 75138308 shares traded in last market. With a market cap of 2.07M USD, the company’s current market price of $2.46 came rising about 60.78 while comparing to the previous closing price of $1.53. In past 52 weeks, the stock remained buoying in the range of price level as high as $945.15 and as low as $1.51. In the recent trading on the day, stock has struck highest price mark of $1.81 while lowest mark touched by it was $7.87.

Taking a look at 20-day trading activity of Psyence Biomedical Ltd (PBM) gives us an average price of $2.6000, while its current price level is -99.74% below from 52-week high level whereas it is 62.91% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $4.7500 while that of 200 days or SMA-200 reads an average of $36.9000. A closer look into the stock’s movement over the week reveals that its volatility is standing at 76.87% during that period while stretching the period over a month that decreases to 38.20%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 39.53 which implies that the stock is in neutral territory.

Over the week, PBM’s stock price is moving 20.59% up while it is -37.52% when we observe its performance for the past one month. Year-to-date it is -99.65% down and over the past year, the stock is showing a downside performance of -99.71%.

The company is expected to be releasing its next quarterly report in January, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.

Currently, Psyence Biomedical Ltd’s total number of outstanding shares is 0.72M with 11.14% of that held by the insiders while 37.09% of its common stock has been owned by the institutions. Company’s return on equity (ROE) at 1.27%. Stock’s beta reads -0.37. Its return on asset (ROA) is 1.13% on average.